Funding for this research was provided by:
Health Technology Assessment Programme (15-40-05)
Received: 26 October 2020
Accepted: 29 April 2021
First Online: 18 May 2021
: The study was approved by Wales Research Ethics Committee 6. Informed consent was obtained from all participants.
: Not applicable.
: Outside of the submitted work, CH reports speaker fees from Astellas Medtronic Allergan, an educational grant from Medtronic and consultant fees from Teleflex Medical. KH is a member of the NIHR HTA General Committee, the HTA Funding Committee Policy Group and the Research Professors Panel. MJD reports personal fees from Astellas and Ferring.One of the index tests used in the main PriMUS study, Flowtaker, was developed by a team from the Newcastle upon Tyne Hospitals NHS Foundation Trust (NuTH) and Newcastle University, including AB and MD. In 2014, the device was licenced to MMS (Enschede, The Netherlands) and royalties from the sale of the device were paid to NuTH (not to the individuals). MMS was subsequently acquired by Laborie who removed Flowtaker from the market in January 2018. AB and MD have a patent EP2741671A1 with royalties paid to the Newcastle upon Tyne Hospitals NHS Foundation Trust.